Clinical Pharmacology Adaptive Therapy Group

Department/Directorate Information: Division of Clinical Studies - Clinical Trials and Statistics Unit (ICR-CTSU) The ICR-CTSU is a Cancer Research UK-funded, internationally recognised methodologist led clinical trials unit, providing cancer-focused clinical trial research expertise. We lead pioneering, efficient, high-quality, and impactful trials across the phases. Our expertise ranges from experimental medicine early phase studies exploring biological efficacy to trials which may deliver widespread change to routine practice, underpinned by applied methodology to drive forward clinical trial innovation. See our clinical trials Role Summary The Group Leader will lead a component of ICR-CTSU’s portfolio of clinical trials research. The post holder will join an existing faculty and seek to further develop and grow the portfolio in line with ICR-CTSU’s overall strategy; taking responsibility for a number of ongoing trials as well as the development of new trials. There will be the opportunity to develop and grow a team including the potential for a Postdoctoral Training Fellow and/ or a Trial Manager. We seek an experienced statistician / biostatistician with a strong research interest in clinical trials methodology and a passion for direct involvement in the oversight and leadership of academic clinical trials. The successful candidate will work closely with the Director of ICR-CTSU to further enhance the Unit’s internationally recognised strength in clinical trial design, conduct and analysis. The post holder will be expected to make a substantial independent intellectual contribution to clinical trials projects and be proactive in leading and contributing to broad initiatives that enhance the overall effectiveness of ICR-CTSU. The appointee will contribute to the overall scientific life of the ICR including the newly established ICR/Royal Marsden Hospital’s Centre for Trials and Population Data Science, by providing mentorship to more junior colleagues and acting as an academic leader. We seek an individual who will work closely and collaboratively with other faculty/Group Leaders at the ICR and with international/national key opinion leaders to extend the breadth and depth of ICR-CTSU’s biologically rich clinical trials portfolio. In partnership with clinical opinion leaders, this individual will generate research funds to conduct and deliver clinical trials research at the international forefront. Presentation at national and international conferences, production of top-quality research outputs and substantial professional contribution to wider clinical trial network bodies are expected. Enthusiasm for team-based science in a collaborative interdisciplinary environment is essential. The appointment will be based on track record and the ability and willingness to engage in team science. The successful appointee will have access to ICR’s successful PhD training programme and core facilities. Key Requirements Higher degree (MSc or PhD) in medical statistics/biostatistics or an allied field (e.g. public health, epidemiology, data science) with relevant work experience Significant experience as a clinical trials, medical statistician or bio-statistician within the academic or commercial sector; a blend of both would be highly desirable A desire to apply existing and novel statistical methods to the requirements of a diverse range of statistical problems A broad understanding of cancer research Ability to lead a Clinical Trials Unit based research group As part of your online application, you will be required to upload your full CV which will pre-populate your application form, you will also be asked to attach the following documents and failure to do so will mean your application cannot be considered on this occasion: Lists of major publications, achievements, research grants and distinctions. A PDF of a maximum of five key publications, or other research outputs (e.g. patents) that best demonstrate previous productivity or a single document giving hyperlinks to these outputs. You must also complete the personal statement section of the application form in the format of a cover letter including the names and contact details of three academic referees Joining as a Group Leader, you will be given outstanding support to help you to continue to develop in your career. Along with a start-up package of funding, you will also have access to resources to establish your group, including support for recruiting key group members, such as PhD students and postdoctoral researchers. We encourage all applicants to access the job pack attached for more detailed information regarding this role. For an informal discussion regarding the role, please contact Professor Emma Hall ([email protected])

To work in close collaboration with Professor Sebastian Nijman, we are seeking to recruit a Group Leader to lead an independent research group that contributes directly to target identification and small molecule drug discovery; lead and participate in multidisciplinary drug discovery research teams. Experience Proven ability to contribute to drug discovery activities Proven scientific productivity and leadership by means of high-profile publication and/or patents Skills in co-ordinating, planning and executing novel (target) biology studies to a standard of international excellence Demonstrated expertise in building and running biological assays for use in drug discovery test cascades Ability to rapidly assimilate relevant information, identify new research opportunities, and clearly communicate recommendations Evidence of a strategic and inclusive approach to decision making and performance management Excellent track record of cross-disciplinary collaboration Effective stakeholder engagement through strong relationship building and communication skills Evidence of the ability to lead and manage research staff, with a focus on performance and development Division of Cancer Therapeutics The Division of Cancer Therapeutics has an unrivalled track record at discovering novel cancer treatments for the personalised treatment of cancer. Within the Division, the Centre for Cancer Drug Discovery (CCDD) is a multidisciplinary 'bench to bedside' centre, comprising 160 staff dedicated to the discovery and development of novel therapeutics for the treatment of cancer. We are one of the largest academic cancer drug discovery groups in the world and, together with our collaborators, have discovered 21 preclinical development candidates, 13 of which have been progressed to clinical evaluation, many with our partners in the ICR/Royal Marsden Drug Development Unit. Our drug abiraterone (Zytiga) has been approved in the US, Canada and Europe for late-stage prostate cancer whereas the pan-AKT inhibitor capiversitib is on the market for breast cancer since 2023. The CCDD’s mission is to develop “first in class” personalised medicines for patient benefit. We implement innovative drug discovery technologies, discover novel mechanism-based drugs, and develop these as rapidly as possible from the laboratory through to hypothesis-testing early clinical trials. We publish our work extensively and have a large network of collaborations with academia, biotechnology companies, and the pharmaceutical industry. Our teams are dedicated to the discovery of small molecule drug candidates, and to the development of high-quality chemical probes to enable new cancer biology research. The Division of Cancer Therapeutics is based in state-of-the art laboratories in the Centre for Cancer Drug Discovery building, opened in 2020 on the ICR Sutton campus. About The Institute of Cancer Research We are one of the world’s oldest and most influential cancer research institutes with an outstanding record of achievement dating back more than 100 years. We are world leaders in identifying cancer genes, discovering cancer drugs and developing precision radiotherapy. Together with our hospital partner The Royal Marsden, we are consistently rated in the top four centres for cancer research and treatment worldwide. As well as being a world-class institute, we are a college of the University of London. We are consistently in the top performing universities in the league table of university research quality compiled from the Research Excellence Framework (REF 2014 & 2021).